{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T17:25:29Z","timestamp":1780421129762,"version":"3.54.1"},"reference-count":45,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T00:00:00Z","timestamp":1456444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oral Diseases"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To describe the clinical characteristics and evolution of our series of medication\u2010related osteonecrosis of the jaws (<jats:styled-content style=\"fixed-case\">MRONJ<\/jats:styled-content>) associated with denosumab in osteoporotic patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and Methods<\/jats:title><jats:p>We present 10 new cases of <jats:styled-content style=\"fixed-case\">MRONJ<\/jats:styled-content> in patients receiving denosumab for osteoporosis. We describe the mean doses of denosumab, previous bisphosphonate intake, and the clinical characteristics associated with the osteonecrosis, such as local contributing factors, symptoms, and evolution after treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean number of denosumab doses was 3.4\u00a0\u00b1\u00a02.2. In 90% of patients, there was <jats:italic>a prior<\/jats:italic> history of oral bisphosphonate intake, with a mean duration of 46.78\u00a0\u00b1\u00a025.11\u00a0months. The most common local factor was dental extraction (6 cases; 60%), and most cases had necrotic bone exposure (9\/10, 90%). Sclerosis of the bone was the most common radiographic finding. Stage 1 was the most common <jats:styled-content style=\"fixed-case\">ONM<\/jats:styled-content> stage, found in 80%. \u2018Cure\u2019 after conservative treatments was obtained in 71.4%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Most of our cases were in the early stages of <jats:styled-content style=\"fixed-case\">MRONJ<\/jats:styled-content>, and the success rate after conservative treatment was high.<\/jats:p><\/jats:sec>","DOI":"10.1111\/odi.12447","type":"journal-article","created":{"date-parts":[[2016,1,28]],"date-time":"2016-01-28T08:28:01Z","timestamp":1453969681000},"page":"324-329","source":"Crossref","is-referenced-by-count":37,"title":["Medication\u2010related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis"],"prefix":"10.1111","volume":"22","author":[{"given":"J","family":"Bagan","sequence":"first","affiliation":[{"name":"Oral Medicine University of Valencia Valencia Spain"},{"name":"Service of Stomatology and Maxillofacial Surgery University General Hospital Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Peydr\u00f3","sequence":"additional","affiliation":[{"name":"Oral Medicine Valencia University Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Calvo","sequence":"additional","affiliation":[{"name":"Rheumatology University General Hospital Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Leopoldo","sequence":"additional","affiliation":[{"name":"Service of Stomatology and Maxillofacial Surgery University General Hospital Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Oral Medicine Valencia University Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Bagan","sequence":"additional","affiliation":[{"name":"Oral Medicine Universidad Europea Valencia Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,2,26]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcms.2013.05.014"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2012.02.009"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.24.2927"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1597"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1570"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.10.008"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.0809010"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.6118\/jmm.2015.21.1.1"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1429-y"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2011.01.014"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544060-00001"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809493"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.14219\/jada.archive.2012.0323"},{"key":"e_1_2_6_15_1","volume-title":"Prolia (denosumab)","author":"European Medicines Agency","year":"2015"},{"key":"e_1_2_6_16_1","volume-title":"FDA approves new injectable osteoporosis treatment for postmenopausal women","author":"Food and Drug Administration","year":"2010"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.14219\/jada.archive.2011.0220"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.3304"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2405"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2013.05.012"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S7727"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2009.03.050"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2012.08.439"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h3783"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-2391(03)00720-1"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0432-z"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-013-2437-z"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/adj.12217"},{"key":"e_1_2_6_29_1","first-page":"3707","article-title":"Osteonecrosis of the jaw in patient with denosumab therapy","volume":"7","author":"Olate S","year":"2014","journal-title":"Int J Clin Exp Med"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcms.2013.05.038"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1479"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0426"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-013-0561-6"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.01.002"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjoms.2014.01.021"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2014.04.031"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31826aec2b"},{"key":"e_1_2_6_38_1","first-page":"248","article-title":"Possible denosumab\u2010induced jaw osteonecrosis in the treatment of osteoporosis. A case report","volume":"38","author":"Selvi Sabater P","year":"2014","journal-title":"Farm Hosp"},{"key":"e_1_2_6_39_1","first-page":"1793","article-title":"Denosumab and anti\u2010angiogenetic drug\u2010related osteonecrosis of the jaw: an uncommon but potentially severe disease","volume":"33","author":"Sivolella S","year":"2013","journal-title":"Anticancer Res"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-2964-2"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjoms.2009.08.030"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2015.09.028"},{"key":"e_1_2_6_43_1","first-page":"c78","article-title":"Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw","volume":"78","author":"Troeltzsch M","year":"2012","journal-title":"J Can Dent Assoc"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.4317\/medoral.18812"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.4317\/medoral.20092"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2269"}],"container-title":["Oral Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fodi.12447","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/odi.12447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T17:50:41Z","timestamp":1695750641000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/odi.12447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,26]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1111\/odi.12447"],"URL":"https:\/\/doi.org\/10.1111\/odi.12447","archive":["Portico"],"relation":{},"ISSN":["1354-523X","1601-0825"],"issn-type":[{"value":"1354-523X","type":"print"},{"value":"1601-0825","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,26]]}}}